Genes explain GLP‑1 swings
Researchers found that genetic differences help explain why some people lose lots of weight on GLP‑1 drugs while others get side effects — a step toward personalizing obesity treatment rather than using a one‑size‑fits‑all approach. ( ) The analysis drew on data from almost 28,000 patients and points to variants in GLP1R and GIPR that correlate with both larger weight loss and higher rates of nausea or vomiting — findings reporters say could change who doctors prescribe semaglutide or tirzepatide to. ( )
These drugs copy gut hormones that tell the brain “you’ve eaten” and tell the stomach to empty more slowly, which is why semaglutide and tirzepatide can cut appetite as well as body weight. Semaglutide mainly targets the glucagon-like peptide-1 receptor, while tirzepatide hits that receptor and a second one called the glucose-dependent insulinotropic polypeptide receptor. (nature.com, nature.com) That sounds simple until you look at real patients. Some people on these injections lose more than 20% of their body weight, some lose less than 5%, and side effects like nausea or vomiting hit some users hard while others barely notice them. (nature.com, nature.com) The new study asked whether part of that gap is written into the receptors themselves. If the drug works by pressing a molecular doorbell on a cell, a small inherited change in the doorbell could change how loudly the signal rings. (nature.com, nature.com) Researchers analyzed genetic and self-reported treatment data from nearly 28,000 people, most drawn from 23andMe participants who had used a glucagon-like peptide-1 drug for weight loss. They then scanned the genome for variants linked to weight change and to nausea or vomiting. (nature.com, nature.com) The clearest signal sat in GLP1R, the gene that builds the glucagon-like peptide-1 receptor. A missense variant called rs10305420 was tied to greater weight loss, with carriers losing about 0.76 kilograms more per copy of the variant than non-carriers. (nature.com, neurosciencenews.com) A second signal showed up in GIPR, the gene for the glucose-dependent insulinotropic polypeptide receptor that tirzepatide also targets. Variants there were linked not just to weight loss differences but also to higher odds of nausea and vomiting. (nature.com, statnews.com) That overlap is the part doctors will watch closely. The same biology that seems to make the drug work better in some people may also make the ride rougher, which helps explain why “strong responder” and “bad side effects” can travel together. (nature.com, nature.com) The paper does not say genes are destiny. The reported effects were measurable but modest, and the authors say age, diet, dose, adherence, other medicines, and many other genes still shape what happens after the first injection. (nature.com, nature.com) It also does not mean a cheek swab will decide prescriptions next month. Nature’s news article says the work is a proof of principle, not a ready-made clinic test, and outside experts said the findings need replication in more diverse groups and in health-record datasets with cleaner outcome tracking. (nature.com, statnews.com) But it does point to a different future for obesity medicine. Instead of giving the same drug to everyone and waiting months to see who loses weight or who quits from nausea, doctors could eventually use genetics to estimate who is more likely to benefit from semaglutide, who might do better on tirzepatide, and who may need slower dosing or another option entirely. (nature.com, theguardian.com)
